| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA905: Upadacitinib for previously treated moderately to severely active Crohn's disease |
|
Medicine details |
|
| Medicine name | upadacitinib (Rinvoq®) |
| Formulation | oral |
| Reference number | 4252 |
| Indication | Treatment of adult patients with moderate to severe active Crohn’s disease (CD) who have had an inadequate response or intolerance to one or more conventional and/or biologic therapies |
| Company | AbbVie Ltd |
| BNF chapter | Gastro-intestinal system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/06/23 |
| NICE guidance | TA905: Upadacitinib for previously treated moderately to severely active Crohn's disease |
| Commercial arrangement | PAS |